Stock Ratings / Health Care / AXGN / earnings

ITGR (67) MDT (72) SGRY (66) WRBY (52) ⌘ Pro Terminal →

Axogen Inc. (AXGN) Next Earnings Date & Expected ±9.2% Move

$49.63 +0.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Axogen Inc. (AXGN) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AXGN)Realized 20D OHLCV Swing Band: ±9.2%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±9.2% Swing Band

±$4.57 Expected Swing

MODEL EARNINGS SETUP GAUGE

AXGN Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $-0.26 • YoY Revenue Growth: 20.2%

Model Bullish Setup (54/100)Model Risk Weight (46/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$225.2M	-$15.7M	-$2.9M	74.3%
FY 2024	2024-12-31	$187.3M	-$10.0M	$1.4M	75.8%
FY 2023	2023-12-31	$159.0M	-$21.7M	-$12.9M	74.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AXGN)

✓Walkthrough of AXGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AXGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.42%⚡ TESTING RESISTANCE

2026-11-01O $49.25H $49.63L $49.25C $49.63VOL 2.28M

RES: $51.08SUP: $33.70SMA50: $42.84SMA200: $39.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AXGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AXGN Butterfly Map → + Track AXGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

11.2%/yr Implied 5Y Growth

vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AXGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AXGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AXGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AXGN)

Health Care Rank #136 of 188 ⚔️ ITGR vs AXGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AXGN vs. ITGR, MDT, SGRY, WRBY)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (3 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Axogen Inc. (AXGN) ranks #136 by composite RQD confidence (54/100, grade D+) and #183 by equity capitalization ($2.96B). Within this direct 5-issuer industry benchmark cohort, ITGR leads on earnings valuation at 41.8x trailing P/E, while SGRY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. MDT currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with AXGN at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AXGN ACTIVE Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	Benchmark Subject
ITGR Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	-0.02%	$4.30B	/itgr-vs-axgn →
MDT Medtronic plc.	B	72/100	—	65.0%	7.8%	+2.46%	$124.22B	/mdt-vs-axgn →
SGRY Surgery Partners Inc.	C+	66/100	—	—	9.9%	-0.13%	$3.04B	/sgry-vs-axgn →
WRBY Warby Parker Inc.	D+	52/100	—	54.0%	-1.7%	+0.66%	$3.04B	/wrby-vs-axgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000805928

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Axogen Inc. (AXGN) reported GAAP revenue of $225.2M (+20.2% vs. FY2024 revenue of $187.3M , and +41.6% cumulative change since FY2023) , GAAP net income of -$15.7M, operating cash flow of $812.0K, and free cash flow of -$2.9M (-304.5% YoY). On the balance sheet, AXGN closed FY2025 with $221.7M in total assets against $48.4M in total debt (Altman Z-Score: 18.64, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$225.2M	-$15.7M	$812.0K	-$2.9M	$221.7M	$48.4M
FY2024 (FY)	2024-12-31	$187.3M	-$10.0M	$4.5M	$1.4M	$203.7M	$47.5M
FY2023 (FY)	2023-12-31	$159.0M	-$21.7M	-$5.7M	-$12.9M	$1.63B	$381.5M

3. AXGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AXGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Axogen Inc. (NASDAQ: AXGN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $49.63 (+0.77% 1D, market cap $2.96B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 188 tracked Health Care issuers, AXGN ranks #136 in composite RQD confidence.

How does AXGN compare to ITGR and MDT in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), AXGN carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 74.3%, and ROIC of -2.6%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and MDT (Medtronic plc.) posts a B grade (72/100 RQD, P/E N/A, ROIC 7.8%, cap $124.22B). Among the 5-stock peer group, ITGR leads on earnings multiple (41.8x) while SGRY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AXGN?

Per AXGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000805928), Axogen Inc. generated $225.2M in revenue (+20.2% YoY), -$15.7M in net income, and -$2.9M in free cash flow against $221.7M in total assets and $48.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AXGN trading relative to its 50-day, 200-day, and 52-week technical levels?

AXGN last traded at $49.63 (+0.77% on volume of 2,281,119 shares), positioning the stock +15.85% above its 50-day simple moving average ($42.84) and +25.14% above its 200-day simple moving average ($39.66). Across its 52-week range of $21.68 to $52.91, AXGN sits at the 89.5% percentile with a 14-day RSI of 74.3 (OVERBOUGHT (>70)) and an implied next-earnings move of ±9.2% ($45.06 to $54.20).